Prestige Consumer Healthcare Inc.PBH

NYSEHealthcarePharmaceutical Preparations
Price (close)
$45.65
Market cap
$2.2B
P/E
12.6x
Revenue (TTM)
$1.1B
Net income
$172.0M
Dividend yield
—
1-year total return
-27.2%
Net margin
15.6%
Revenue growth
-1.4%
Debt / equity
1.05x

What Prestige Consumer Healthcare Inc. does.

Unless otherwise indicated by the context, all references in this Annual Report on Form 10-K to “we,” “us,” “our,” the “Company” or “Prestige” refer to Prestige Consumer Healthcare Inc. and our subsidiaries. Prior to August 17, 2018, the Company's name was Prestige Brands Holdings, Inc. Reference to a year (e.g., “2026”) refers to our fiscal year ended March 31 of that year.

We formed as a Delaware corporation in 1996 and are engaged in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name, over-the-counter (“OTC”) health and personal care products to mass merchandisers, drug/drug wholesale, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. We use the strength of our brands, our established retail distribution network, a low-cost operating model and our experienced management team to our competitive advantage. Our ultimate success is dependent on several factors, including our ability to:

• Develop and execute effective sales, advertising and marketing programs to maintain or grow our market share versus competitors over time;

Revenue and profit, by fiscal year.

Fiscal year202120222023202420252026
Revenue$943.4M$1.1B$1.1B$1.1B$1.1B$1.1B
Net income$164.7M$205.4M-$82.3M$209.3M$214.6M$190.3M
Free cash flow$213.4M$250.3M$221.9M$239.4M$243.3M$246.4M

More on PBH.

Figures from Prestige Consumer Healthcare Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.